Table 1.
CD8+ and CD4+ intratumoral and stromal lymphocytic infiltrate assessed by IHC in DDRD-positive and DDRD-negative breast tumors
| Score | DDRD positive, No. (%) | DDRD negative, No. (%) | P* |
|---|---|---|---|
| Intratumoral | |||
| CD8+ | 65 (100) | 117 (100) | <.001 |
| 3 | 6 (9.2) | 0 (0.0) | |
| 2 | 29 (44.6) | 19 (16.2) | |
| 1 | 25 (38.5) | 68 (58.1) | |
| 0 | 5 (7.7) | 30 (25.6) | |
| CD4+ | 65 (100) | 119 (100) | <.001 |
| 3 | 3 (4.6) | 1 (0.8) | |
| 2 | 13 (20.0) | 3 (2.5) | |
| 1 | 43 (66.2) | 75 (63.0) | |
| 0 | 6 (9.2) | 40 (33.6) | |
| Stromal | |||
| CD8+ | 65 (100) | 117 (100) | <.001 |
| 3 | 20 (30.8) | 8 (6.8) | |
| 2 | 38 (58.5) | 58 (49.6) | |
| 1 | 7 (10.8) | 44 (37.6) | |
| 0 | 0 (0.0) | 7 (6.0) | |
| CD4+ | 65 (100) | 119 (100) | <.001 |
| 3 | 21 (32.3) | 7 (5.9) | |
| 2 | 31 (47.7) | 32 (26.9) | |
| 1 | 13 (20.0) | 66 (55.5) | |
| 0 | 0 (0.0) | 14 (11.8) |
*
P values were calculated using a two-sided Fisher’s exact test. DDRD = DNA damage response–deficient; IHC = immunohistochemistry.